Clin Mol Hepatol > Accepted Articles
Atezolizumab and bevacizumab for hepatocellular carcinoma: how to approach salvage therapy for non-responders?
Naoshi Nishida
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi Osaka-Sayama, 589-8511, Japan
Correspondence :  Naoshi Nishida ,
Tel: +81-72-366-0221 (Ext. 3525), Fax: +81-72-367-2880, Email: naoshi@med.kindai.ac.jp
Received: May 2, 2024   Accepted: May 3, 2024

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 1709
TOTAL : 2099225
Close layer